CNTG Centogene NV: Prakiraan wutah bathi kanggo taun ngarep

Analyst EPS growth targets for the next 12 months on the GURU.Markets platform chart demonstrate that the indicator value reaches 0.00. Centogene N.V. (CNTG) maintains a crisis-resilient business, as the demand for pathology diagnostics remains constant. Ownership of an exclusive biobank creates a technological barrier, ensuring a steady stream of profit. Simultaneously, Centogene N.V. (CNTG) is developing multi-omics markers through partnerships with pharma behemoths to sustain its pace of innovation.

The expected earnings per share (EPS) growth rate measures the market's aggregate confidence in the business's scalability and its ability to generate future cash flow. By analyzing the EPS growth forecasting model for the coming year, an investor assesses the operational resilience of Centogene N.V. (CNTG) through the lens of pharma behemoths' demand for its AI diagnostics and the efficiency of its genetic database management.